Conducted by Chris O’Brien Lifehouse and Garvan Institute of Medical Research, the study involved the analysis of blood samples for a methylated copy of the glutathione S-transferase gene (mGSTP1) both before and during treatment.
At the beginning of the study, the blood test identified the biomarker in 81% of patients. The tests were then repeated after two cycles of chemotherapy with docetaxel and revealed the absence of the biomarker in 53% of participants.
